Clinical trials: Neoadjuvant Melanoma
Uveal Melanoma
Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma
Neoadjuvant RBP-01 in patients with primary uveal melanoma.
- Trial name
- Uveal Melanoma (NCT07747935)
- Testing
- RBP-01
- Volunteers
- 30 people
- Sponsor
- ReBio Pharma
Melanoma, Acral Melanoma
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.
- Conditions
- Melanoma, Acral Melanoma, Temozolomide, Apatinib
- Trial name
- NCT05512481
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
This phase I/II trial tests the safety and side effects of LN-144 (Lifileucel) and pembrolizumab in treating patients with stage IIIB-D or stage IV melanoma that has spread to nearby tissue or lymph nodes.
- Conditions
- Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Trial name
- NCT05176470
- Testing
- Cyclophosphamide, Fludarabine, Lifileucel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Richard Wu
Cutaneous Melanoma
Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma
This study evaluates the clinical safety and tolerability, and the immunological effects of local intradermal injection of tremelimumab in patients with clinical stage I/II melanoma patients undergoing a sentinel node biopsy…
- Trial name
- NCT04274816
- Testing
- Tremelimumab
- Volunteers
- 13 people
- Sponsor
- A.J.M. van den Eertwegh
Melanoma (Skin Cancer)
Exploratory Study With Parallel Controls on the Safety and Efficacy of Neoadjuvant Low Branched-Chain Amino Acid Diet in Combination With Anti-PD-1 Monoclonal Antibody for Stage III Melanoma
1. Primary Objective: To evaluate the safety of a low branched-chain amino acid diet (60% of the normal dietary BCAA content) combined with anti-PD-1 monoclonal antibody as neoadjuvant therapy in patients with stage III melanoma…
- Trial name
- NCT07586891
- Testing
- Low Branched-Chain Amino Acid Diet
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xijing Hospital
Metastatic Melanoma
Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI).
- Trial name
- BBI (NCT01743157)
- Testing
- Biochemo + bevacizumab then ipilimumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- California Pacific Medical Center Research Institute
Unresectable Malignant Neoplasm, Melanoma
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
This study is being done to see if using the study drug, pembrolizumab, can shrink down melanoma tumors enough so that they will be small enough to cut out, so that there will be no cancer left in the body.
- Conditions
- Unresectable Malignant Neoplasm, Melanoma, Metastatic Melanoma, Stage IV Melanoma
- Trial name
- NeoPembroMel (NCT02306850)
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- St. Louis University
Uveal Melanoma
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
- Trial name
- NCT05907954
- Testing
- Darovasertib
- Where
- 18 sites in United States, Australia and 5 more
- Volunteers
- 160 people
- Sponsor
- IDEAYA Biosciences
Melanoma Stage III
The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma
This Phase 2, multi-center, single-arm study evaluates the safety, tolerability, and activity of neoadjuvant PRTX007 in combination with pembrolizumab in participants with resectable Stage III melanoma.
- Trial name
- INFLECTION-003 (NCT07565285)
- Testing
- PRTX007, Pembrolizumab
- Where
- 7 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Primmune Therapeutics, Inc.
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma.
- Conditions
- Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
- Trial name
- NCT03698019
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 815 sites in United States
- Volunteers
- 313 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Malignant Melanoma
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
- Conditions
- Melanoma, Malignant Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma
- Trial name
- NCT01321437
- Testing
- therapeutic conventional surgery, laboratory biomarker analysis, Axitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, Irvine
MelanomaCutaneous Melanoma Resectable, Melanoma
Neoadjuvant RP2 + Nivolumab in Patients With Melanoma
This is a Phase II study is being done to determine whether a new combination of therapies is safe and effective for adults to treat Melanoma before surgery.
- Trial name
- NCT07862530
- Testing
- RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Yana Najjar
Cutaneous Melanoma
Neoadjuvant Atezolizumab in Cutaneous Melanoma
The purpose of this research study is to see whether using atezolizumab before surgery is safe and does not cause side effects that delay surgery in participants with cutaneous melanoma that has not spread to other areas of the…
- Trial name
- NCT04020809
- Testing
- Atezolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Methodist Hospital Research Institute
Brain Metastases, Adult
Neoadjuvant Immunotherapy in Brain Metastases
The purpose of this phase 2 study is to assess the feasibility and efficacy of neoadjuvant immunotherapy in patients with previously untreated, surgically-resectable, solid tumor brain metastases.
- Trial name
- NCT04434560
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sarah Sammons, MD
Melanoma
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
This open label, single country trial will test if local injection of low-dose ipilimumab and nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma patients.
- Trial name
- MARIANE (NCT06240143)
- Testing
- Ipilimumab, Nivolumab
- Where
- 6 sites in Netherlands
- Volunteers
- 96 people
- Sponsor
- The Netherlands Cancer Institute
Melanoma (Skin)
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.
- Trial name
- NCT07527325
- Testing
- Fianlimab, Cemiplimab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, Irvine
Melanoma
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
This study will evaluate the clinical and pathological response to vemurafenib and cobimetinib in the neoadjuvant treatment of patients with histologically confirmed, BRAF V600 mutation-positive Stage IIIB and C melanoma.
- Trial name
- NCT02036086
- Testing
- Vemurafenib, Cobimetinib
- Where
- 3 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Sunnybrook Health Sciences Centre
Melanoma Stage III, Melanoma
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Subjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of adjuvant nivolumab or ipilimumab plus…
- Trial name
- NCT04013854
- Testing
- nivolumab, Ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
This trial studies how well vemurafenib, cobimetinib, and atezolizumab work in treating patients with high-risk stage III melanoma.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT03554083
- Testing
- Atezolizumab, Cobimetinib, Tiragolumab
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Mayo Clinic
Head and Neck Mucosal Melanomas
Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma
The main objective will be to estimate the disease free survival (DFS) of patients with resectable head and neck mucosal melanomas treated by neo-adjuvant anti-PD1 (in combination or not with lenvatinib) followed by surgery…
- Trial name
- IMMUQ (NCT03313206)
- Testing
- Pembrolizumab, Surgery, IMRT
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris